IPO registrations (S-1, F-1) · Registrants
Cadrenal Therapeutics, Inc.
- SEC CIK
- 1937993 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2022-09-22, last 2025-12-29; 3 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2023-01-23; declared effective 2023-01-19
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 822 A1A NORTH, SUITE 306, Ponte Vedra, FL 32082
- EIN
- 88-0860746
- Ticker
- CVKD (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Cadrenal Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $5.00 per share (424B4 filed 2023-01-23, an initial public offering)
- Shares sold
- 1,400,000 (1,400,000 by the company, 1,704,783 by selling holders)
- Gross proceeds
- $7,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CVKD
- Lead underwriters
- Boustead Securities
- Syndicate
- Sutter Securities, Inc; Revere Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CADRENAL THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CADRENAL THERAPEUTICS INC. Fuzzy (name and state)
- Form 5500 plan sponsor: CADRENAL THERAPEUTICS INC EXACT (EIN (EXACT))
- Form D issuer: Cadrenal Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Cadrenal Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: Quang X Pham Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer,TenPercentOwner))
Filings 19
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2022-09-22 | S-1 | S-1 (registration) | Cadrenal Therapeutics, Inc. | 0001213900-22-058071 ↗ |
| 2022-10-11 | S-1/A | S-1/A (amendment) | Cadrenal Therapeutics, Inc. | 0001213900-22-062909 ↗ |
| 2022-10-17 | S-1/A | S-1/A (amendment) | Cadrenal Therapeutics, Inc. | 0001213900-22-064170 ↗ |
| 2022-12-06 | S-1/A | S-1/A (amendment) | Cadrenal Therapeutics, Inc. | 0001213900-22-077850 ↗ |
| 2022-12-08 | S-1/A | S-1/A (amendment) | Cadrenal Therapeutics, Inc. | 0001213900-22-078525 ↗ |
| 2022-12-28 | S-1/A | S-1/A (amendment) | Cadrenal Therapeutics, Inc. | 0001213900-22-083009 ↗ |
| 2023-01-17 | S-1/A | S-1/A (amendment) | Cadrenal Therapeutics, Inc. | 0001213900-23-002924 ↗ |
| 2023-01-19 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-23-000131 ↗ |
| 2023-01-23 | 424B4 | 424B4 (final prospectus) | Cadrenal Therapeutics, Inc. | 0001213900-23-004433 ↗ |
| 2023-01-23 | 424B4 | 424B4 (final prospectus) | Cadrenal Therapeutics, Inc. | 0001213900-23-004435 ↗ |
| 2023-07-24 | S-1 | S-1 (registration) | Cadrenal Therapeutics, Inc. | 0001213900-23-059047 ↗ |
| 2023-07-28 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-23-002217 ↗ |
| 2024-03-20 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-24-000694 ↗ |
| 2024-04-02 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-24-000826 ↗ |
| 2024-11-22 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-24-003563 ↗ |
| 2025-12-29 | S-1 | S-1 (registration) | Cadrenal Therapeutics, Inc. | 0001213900-25-125526 ↗ |
| 2025-12-31 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-26-000024 ↗ |
| 2026-04-29 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-26-001386 ↗ |
| 2026-07-20 | EFFECT | EFFECT (declared effective) | Cadrenal Therapeutics, Inc. | 9999999995-26-002367 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-17 | S-1/A | registration statement | $5.00 | 1,704,783 | $7,000,000 | Nasdaq CVKD | 2 | primary document; price table, shares headline, proceeds table, cover names 2 | document ↗ | |
| 2023-01-23 | 424B4 | final prospectus | $5.00 | 1,400,000 | $7,000,000 | Nasdaq CVKD | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| LOSORDO DOUGLAS W | Officer | Chief Medical Officer | 3 | 2023–2024 | |
| MURPHY JOHN RAYMOND | Director | 7 | 2023–2025 | ||
| Pham Quang X | Director,Officer,TenPercentOwner | CEO and Chairman; Chairman and CEO; Chairman, CEO and Interim CFO; Chief Executive Officer | 25 | 2023–2026 | person page Fuzzy |
| Szot Matthew K | Officer | Chief Financial Officer | 11 | 2023–2025 | |
| WILSON GLYNN | Director | 4 | 2023–2025 | ||
| Zelenkofske Steven | Director | 3 | 2023–2025 | ||
| Lisicki Robert | Director | 4 | 2023–2025 | ||
| Cole Jeffrey Scott | Officer | Chief Operating Officer | 3 | 2024–2025 | |
| Ferguson James J. III | Officer | Chief Medical Officer | 2 | 2025 | |
| Golden Lee Scott | Director | 2 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-07-15 | Cadrenal Therapeutics, Inc. | Biotechnology | $8,843,849 | $8,843,849 | 1 | 1 |
| 2026-04-06 | Cadrenal Therapeutics, Inc. | Biotechnology | $7,923,235 | $7,923,235 | 1 | 1 |
| 2025-12-31 | Cadrenal Therapeutics, Inc. | Biotechnology | $4,396,329 | $4,396,329 | 4 | 1 |
| 2024-11-14 | Cadrenal Therapeutics, Inc. | Biotechnology | $9,428,594 | $9,428,594 | 5 | 1 |
| 2023-07-18 | Cadrenal Therapeutics, Inc. | Biotechnology | $7,500,001 | $7,500,001 | 1 | 1 |
| 2022-12-08 | Cadrenal Therapeutics, Inc. | Biotechnology | $1,000,000 | $250,000 | 2 | 1 |
| 2022-07-25 | Cadrenal Therapeutics, Inc. | Biotechnology | $2,000,000 | $150,000 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CADRENAL THERAPEUTICS INC. | FL | State business registries | name and state |
| Business registration | CADRENAL THERAPEUTICS, INC. | FL | State business registries | name and state |
| Plan sponsor | CADRENAL THERAPEUTICS INC | FL | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Cadrenal Therapeutics, Inc. | FL | Form D private offerings | CIK (EXACT) |
| SEC filer | Cadrenal Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | CADRENAL THERAPEUTICS INC. | FL | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | CADRENAL THERAPEUTICS INC | EIN (EXACT) | ||
| Person page | Quang X Pham | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer,TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, FL first:
- SANO CORP FL
- CTT PHARMACEUTICAL HOLDINGS, INC. FL
- Inhibitor Therapeutics, Inc. FL
- GENEREX BIOTECHNOLOGY CORP FL
- BIOMOLECULAR LIFE HOLDINGS, INC. FL
- Alaunos Therapeutics, Inc. FL
- ORAGENICS INC FL
- Polomar Health Services, Inc. FL
- ACCENTIA BIOPHARMACEUTICALS INC FL
- NOMAD POWER SOLUTIONS, INC. FL
In other datasets, the same topic (Health) in FL:
- Nonprofit: 414 WELLWOMEN INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health